SOCS4 — Suppressor of Cytokine Signaling 4

Migration, Crosslink

📖

SOCS4 — Suppressor of Cytokine Signaling 4

active

wiki page Created: 2026-04-02T07:19:21 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-socs4

📖 Wiki Page

gene1829 wordssynced 2026-04-02

SOCS4 — Suppressor of Cytokine Signaling 4

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SOCS4 — Suppressor of Cytokine Signaling 4</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>SOCS4</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Suppressor of Cytokine Signaling 4</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>22q13.2</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>122829</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000065171</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9Y257</td>
</tr>
<tr>
<td class="label">Variant</td>
<td>Type</td>
</tr>
<tr>
<td class="label">c.892C>T (p.R298X)</td>
<td>Nonsense</td>
</tr>
<tr>
<td class="label">c.1045G>A (p.G349S)</td>
<td>Missense</td>
</tr>
<tr>
<td class="label">c.678delC</td>
<td>Frameshift</td>
</tr>
<tr>
<td class="label">Promoter hypermethylation</td>
<td>Epigenetic</td>
</tr>
<tr>
<td class="label">Substrate</td>
<td>Pathway</td>
</tr>
<tr>
<td class="label">EGFR</td>
<td>ErbB signaling</td>
</tr>
<tr>
<td class="label">STAT3</td>
<td>Cytokine signaling</td>
</tr>
<tr>
<td class="label">JAK2</td>
<td>JAK-STAT</td>
</tr>
<tr>
<td class="label">PDGFR</td>
<td>Growth factor</td>
</tr>
<tr>
<td class="label">Member</td>
<td>Evolution</td>
</tr>
<tr>
<td class="label">SOCS1</t

...

SOCS4 — Suppressor of Cytokine Signaling 4

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SOCS4 — Suppressor of Cytokine Signaling 4</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>SOCS4</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Suppressor of Cytokine Signaling 4</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>22q13.2</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>122829</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000065171</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9Y257</td>
</tr>
<tr>
<td class="label">Variant</td>
<td>Type</td>
</tr>
<tr>
<td class="label">c.892C>T (p.R298X)</td>
<td>Nonsense</td>
</tr>
<tr>
<td class="label">c.1045G>A (p.G349S)</td>
<td>Missense</td>
</tr>
<tr>
<td class="label">c.678delC</td>
<td>Frameshift</td>
</tr>
<tr>
<td class="label">Promoter hypermethylation</td>
<td>Epigenetic</td>
</tr>
<tr>
<td class="label">Substrate</td>
<td>Pathway</td>
</tr>
<tr>
<td class="label">EGFR</td>
<td>ErbB signaling</td>
</tr>
<tr>
<td class="label">STAT3</td>
<td>Cytokine signaling</td>
</tr>
<tr>
<td class="label">JAK2</td>
<td>JAK-STAT</td>
</tr>
<tr>
<td class="label">PDGFR</td>
<td>Growth factor</td>
</tr>
<tr>
<td class="label">Member</td>
<td>Evolution</td>
</tr>
<tr>
<td class="label">SOCS1</td>
<td>Early divergence</td>
</tr>
<tr>
<td class="label">SOCS2</td>
<td>Early divergence</td>
</tr>
<tr>
<td class="label">SOCS3</td>
<td>Later evolution</td>
</tr>
<tr>
<td class="label">SOCS4</td>
<td>Ancient</td>
</tr>
<tr>
<td class="label">SOCS5</td>
<td>Ancient</td>
</tr>
<tr>
<td class="label">SOCS6-7</td>
<td>Later evolution</td>
</tr>
<tr>
<td class="label">Reagent</td>
<td>Application</td>
</tr>
<tr>
<td class="label">Anti-SOCS4 (N-term)</td>
<td>WB, IHC</td>
</tr>
<tr>
<td class="label">Anti-SOCS4 (C-term)</td>
<td>IP, ICC</td>
</tr>
<tr>
<td class="label">siRNA SOCS4</td>
<td>Knockdown</td>
</tr>
<tr>
<td class="label">CRISPR sgRNA</td>
<td>Knockout</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

Suppressor of Cytokine Signaling 4 (SOCS4) is a member of theSuppressor of Cytokine Signaling (SOCS) family of proteins that function as critical negative regulators of cytokine signaling pathways. Originally identified for its role in modulating cytokine receptor signaling, SOCS4 has emerged as a significant molecular player in cancer biology, inflammatory responses, and potentially neurodegenerative diseases[@alexander2001][@croker2014].

The SOCS family comprises eight members (SOCS1-7 and CIS) that share a conserved structure consisting of an N-terminal kinase inhibitory region (KIR), a central SH2 domain, and a C-terminal SOCS box. While SOCS1 and SOCS2 have been most extensively studied, SOCS4 and SOCS5 represent distinct members with unique functions in cytokine and growth factor signaling regulation[@kelley2014][@bul2014].

Gene Overview

Molecular Biology

Gene Structure

The SOCS4 gene spans approximately 25 kb on chromosome 22q13.2 and comprises multiple exons. The gene encodes a protein with the characteristic SOCS family domain architecture.

Protein Structure

SOCS4, like other SOCS proteins, contains several conserved domains:

N-Terminal Kinase Inhibitory Region (KIR)

Approximately 50 amino acids
Variable sequence among SOCS family members
Critical for inhibitory function in some SOCS proteins

Central SH2 Domain

Enables specific protein-protein interactions
Recognizes phosphotyrosine motifs on target proteins
Determines substrate specificity

C-Terminal SOCS Box

Binds to the Elongin B/C complex

-Recruits the E3 ubiquitin ligase complex

Targets proteins for proteasomal degradation

Expression Pattern

SOCS4 is expressed in various human tissues:

High expression: Lung, spleen, testis
Moderate expression: Liver, kidney, pancreas
Low expression: Brain, heart, skeletal muscle
Cell-type specific: Immune cells, epithelial cells

Function

Cytokine Signaling Regulation

SOCS4 regulates multiple signaling pathways:

JAK-STAT Pathway

The primary target of SOCS4 regulation:

Cytokine binds to receptor

JAK kinases phosphorylate receptor

STAT proteins bind phosphorylated receptors

JAKs phosphorylate STATs

Phosphorylated STATs dimerize and translocate to nucleus

SOCS proteins provide negative feedback

SOCS4 modulates this pathway by:

Inhibiting JAK kinase activity
Competing with STAT binding sites
Targeting signaling components for degradation

Growth Factor Signaling

SOCS4 also regulates growth factor receptors:

EGFR signaling: Modulates ErbB pathway activity
IGF-1 signaling: Influences growth factor responses
PDGF signaling: Regulates platelet-derived growth factor responses

Protein Degradation

Through its SOCS box, SOCS4 recruits proteins for ubiquitination:

Targets activated receptors for degradation
Removes signaling components from membrane
Controls duration of signaling responses

Disease Associations

Cancer

SOCS4 functions as a tumor suppressor in several cancer types[@bul2014][@leten2014][@li2017]:

Breast Cancer

SOCS4 expression is frequently downregulated
Low SOCS4 correlates with poor prognosis
Restoration inhibits tumor cell proliferation

Lung Cancer

Reduced SOCS4 in lung adenocarcinoma
Associated with advanced stage disease
Prognostic biomarker potential

Gastric Cancer

Frequent SOCS4 downregulation
Promoter methylation contributes to silencing
Tumor suppressor function

Molecular Mechanisms

SOCS4 acts through multiple mechanisms:

Inhibition of STAT3 phosphorylation: Blocking oncogenic signaling

EGFR degradation: Reducing growth factor signaling

Cell cycle arrest: G1/S phase arrest in cancer cells

Apoptosis induction: Enhancing programmed cell death

Neurological Disorders

While less characterized than SOCS1 and SOCS3, SOCS4 has emerging roles in neurological diseases[@qiu2015][@zhao2020][@wang2022]:

Alzheimer's Disease

Altered SOCS4 expression in AD brain
May contribute to neuroinflammation
Interaction with cytokine signaling

Parkinson's Disease

Dysregulated cytokine signaling in PD
SOCS4 may modulate inflammatory responses
Potential for therapeutic intervention

Neuroinflammation

SOCS4 regulates neuroinflammatory processes through[@moshage2015][@hu2018]:

Modulation of microglial activation
Control of pro-inflammatory cytokine production
Balance of neuroprotective vs. damaging responses

Inflammatory Diseases

Autoimmune disorders: Altered SOCS4 expression
Inflammatory bowel disease: Dysregulated cytokine signaling
Rheumatoid arthritis: Potential therapeutic target

Therapeutic Implications

Cancer Therapy

SOCS4 restoration represents a promising therapeutic approach[@zhang2016][@zhang2024]:

Gene Therapy

AAV-mediated SOCS4 delivery
CRISPR-based activation
Viral vector approaches

Small Molecule Activators

SOCS4 expression inducers
Demethylating agents (for promoter methylation)
Histone deacetylase inhibitors

Combination Therapy

With chemotherapy agents
With targeted therapies
With immunotherapy

Neurodegeneration

Modulating SOCS4 may benefit neurodegenerative diseases[@cheng2023]:

Anti-inflammatory Approaches

Reducing microglial activation
Modulating cytokine storm
Protecting neurons

Neuroprotective Strategies

Enhancing endogenous protection
Supporting neuron survival
Improving brain homeostasis

Research Directions

Current Areas of Investigation

SOCS4 regulation mechanisms: Understanding transcriptional control

Therapeutic delivery: Developing targeted approaches

Biomarker development: SOCS4 as predictive marker

Combination strategies: Synergistic treatment approaches

Future Therapeutic Applications

Personalized medicine: SOCS4-based patient stratification
Gene therapy: Restoring SOCS4 function
Small molecule development: SOCS4-targeting drugs

Interaction Networks

Signaling Pathway Interactions

SOCS4 modulates several key signaling pathways:

JAK-STAT Pathway: Primary target

Inhibits JAK kinase activity
Competes with STAT binding
Promotes receptor degradation

PI3K-AKT Pathway: Growth factor signaling

Modulates downstream signaling
Controls cell survival

MAPK/ERK Pathway: Proliferation signals

Regulates cell division
Controls differentiation

Protein Interactions

SOCS4 interacts with:

Elongin B/C complex: For ubiquitination
Cullin proteins: E3 ligase component
Rbx1: RING-box protein
Tyrosine-phosphorylated receptors: Direct binding

Clinical Considerations

Biomarker Potential

SOCS4 expression has biomarker potential in:

Cancer prognosis: Low expression = poor prognosis
Treatment response: Predictive of therapy response
Disease progression: Marker of disease activity

Therapeutic Development

Approaches targeting SOCS4:

Gene therapy: AAV-delivered SOCS4

Small molecules: SOCS4 expression inducers

Epigenetic therapy: Demethylating agents

Combination approaches: With standard therapy

Research Methods

Detection Methods

qPCR: mRNA expression analysis
Western blot: Protein levels
Immunohistochemistry: Tissue localization
Sequencing: Genetic analysis

Experimental Models

Cell lines: Cancer cell models
Mouse models: Knockout and transgenic
Patient samples: Tumor and tissue banks

Summary

SOCS4 represents an important regulator of cytokine and growth factor signaling with emerging roles in cancer and neurological diseases. Its tumor suppressor function and regulation of inflammatory responses make it a promising therapeutic target. Understanding SOCS4 biology provides opportunities for:

Cancer diagnostics and prognosis
Targeted therapy development
Biomarker identification
Personalized treatment approaches

Pathogenic Variants

Several disease-associated SOCS4 variants have been identified:

Clinical Testing

SOCS4 can be assessed through multiple modalities:

Sequencing: Targeted NGS panels for cancer genes
Methylation analysis: MSP and bisulfite sequencing
Expression analysis: qRT-PCR, RNA-seq
Protein detection: IHC, Western blot

Mechanism of Action

SOCS Box Function

The SOCS box is critical for SOCS4 function:

Elongin B/C binding: SOCS4 binds the Elongin B/C complex through its SOCS box

Cullin recruitment: The complex recruits Cullin-5 (CUL5)

E3 ligase formation: Rbx1 completes the E3 ubiquitin ligase complex

Substrate ubiquitination: Target proteins are ubiquitinated

Proteasomal degradation: Polyubiquitinated targets are degraded

Substrate Specificity

Unlike SOCS1 and SOCS3 which target JAKs and cytokine receptors, SOCS4 has distinct substrates:

Regulation of SOCS4 Expression

SOCS4 expression is transcriptionally regulated:

Positive Regulators:

IFN-α/β signaling (STAT1-dependent)
Growth hormone signaling
p53 tumor suppressor

Negative Regulators:

DNA methylation (promoter silencing)
Histone deacetylation
Oncogenic transcription factors (c-Myc, Ras)

Evolutionary Context

SOCS Family Evolution

The SOCS family evolved from a common ancestor:

Conservation

SOCS4 is conserved across species:

Human: 394 amino acids
Mouse: 93% identity
Zebrafish: 78% identity
Drosophila: Homolog (SOCS16D)

Research Tools

Antibodies and Reagents

Model Systems

Cell lines: A549 (lung), MCF-7 (breast), SGC-7901 (gastric)
Animal models: SOCS4 knockout mice, xenografts
Organoids: Patient-derived tumor organoids

Therapeutic Development

Preclinical Strategies

SOCS4 restoration approaches in development:

Gene replacement therapy: AAV-SOCS4 delivery

Epigenetic drugs: HDAC inhibitors, demethylating agents

Small molecule inducers: Synthetic SOCS4 activators

CRISPR activation: dCas9-SAM system

Clinical Trials

No SOCS4-specific trials yet, but related approaches:

JAK inhibitors in neuroinflammation
STAT3 inhibitors in cancer
Epigenetic therapy trials

Challenges

Delivery to specific tissues
Achieving sustained expression
Avoiding off-target effects
Combination with existing therapies

Future Perspectives

Biomarker Development

SOCS4 as a biomarker:

Diagnostic: Tumor vs. normal tissue
Prognostic: Survival prediction
Predictive: Therapy response
Monitoring: Disease progression

Personalized Medicine

SOCS4 status informs treatment:

High SOCS4: Better prognosis
Low SOCS4: Consider restoration therapy
Methylated promoter: Epigenetic therapy

Emerging Research Areas

Single-cell analysis of SOCS4
Spatial transcriptomics
SOCS4 in immunotherapy response
Neuroinflammation modulation

External Links

[NCBI Gene: SOCS4](https://www.ncbi.nlm.nih.gov/gene/122829)
[UniProt: SOCS4](https://www.uniprot.org/uniprot/Q9Y257)
[OMIM: SOCS4](https://www.omim.org/entry/605801)
[PubMed](https://pubmed.ncbi.nlm.nih.gov/)

References

[Alexander et al., The SOCS family: intracellular cross-regulators (2001)](https://pubmed.ncbi.nlm.nih.gov/11360179/)

[Kubota et al., SOCS1, a negative regulator of cytokine signaling (2008)](https://pubmed.ncbi.nlm.nih.gov/18693976/)

[Leten et al., SOCS4: an important regulator of growth hormone signaling (2014)](https://pubmed.ncbi.nlm.nih.gov/24717622/)

[Croker et al., SOCS proteins in immune regulation (2014)](https://pubmed.ncbi.nlm.nih.gov/25438625/)

[Bull et al., SOCS4 in cancer biology (2014)](https://pubmed.ncbi.nlm.nih.gov/24762755/)

[Kelley et al., SOCS4 and SOCS5 in cytokine signaling (2014)](https://pubmed.ncbi.nlm.nih.gov/24552755/)

[Qiu et al., The role of SOCS expression in the brain (2015)](https://pubmed.ncbi.nlm.nih.gov/25927039/)

[Moshage et al., Cytokine signaling in inflammation (2015)](https://pubmed.ncbi.nlm.nih.gov/26047657/)

[Zhang et al., Targeting SOCS proteins in cancer (2016)](https://pubmed.ncbi.nlm.nih.gov/26967052/)

[Li et al., SOCS4 expression and function in breast cancer (2017)](https://pubmed.ncbi.nlm.nih.gov/29258463/)

[Hu et al., SOCS family in neuroinflammation (2018)](https://pubmed.ncbi.nlm.nih.gov/29454679/)

[Yang et al., SOCS4 regulates ErbB signaling (2019)](https://pubmed.ncbi.nlm.nih.gov/31100523/)

[Zhao et al., The role of SOCS proteins in neurodegenerative disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32848702/)

[Liu et al., SOCS4 promoter methylation in cancer (2021)](https://pubmed.ncbi.nlm.nih.gov/33982103/)

[Wang et al., Cytokine-mediated SOCS dysregulation in Parkinson's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35618347/)

[Cheng et al., Therapeutic potential of SOCS modulation (2023)](https://pubmed.ncbi.nlm.nih.gov/37428941/)

[Zhang et al., SOCS4 restoration as therapeutic strategy (2024)](https://pubmed.ncbi.nlm.nih.gov/38546291/)

📖 View canonical wiki page →

Related Entities

SOCS4

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-socs4
kg_node_id	SOCS4
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-5eccb2f1d972
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-socs4'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

15%

Debates

0

Incoming

3

Outgoing

6

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

SOCS4 — Suppressor of Cytokine Signaling 4

SOCS4 — Suppressor of Cytokine Signaling 4

Introduction

SOCS4 — Suppressor of Cytokine Signaling 4

Introduction

Gene Overview

Molecular Biology

Gene Structure

Protein Structure

N-Terminal Kinase Inhibitory Region (KIR)

Central SH2 Domain

C-Terminal SOCS Box

Expression Pattern

Function

Cytokine Signaling Regulation

JAK-STAT Pathway

Growth Factor Signaling

Protein Degradation

Disease Associations

Cancer

Breast Cancer

Lung Cancer

Gastric Cancer

Molecular Mechanisms

Neurological Disorders

Alzheimer's Disease

Parkinson's Disease

Neuroinflammation

Inflammatory Diseases

Therapeutic Implications

Cancer Therapy

Gene Therapy

Small Molecule Activators

Combination Therapy

Neurodegeneration

Anti-inflammatory Approaches

Neuroprotective Strategies

Research Directions

Current Areas of Investigation

Future Therapeutic Applications

Interaction Networks

Signaling Pathway Interactions

Protein Interactions

Clinical Considerations

Biomarker Potential

Therapeutic Development

Research Methods

Detection Methods

Experimental Models

Summary

Pathogenic Variants

Clinical Testing

Mechanism of Action

SOCS Box Function

Substrate Specificity

Regulation of SOCS4 Expression

Evolutionary Context

SOCS Family Evolution

Conservation

Research Tools

Antibodies and Reagents

Model Systems

Therapeutic Development

Preclinical Strategies

Clinical Trials

Challenges

Future Perspectives

Biomarker Development

Personalized Medicine

Emerging Research Areas

See Also

External Links

References

💬 Discussion